• Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation. 2021;144(9). The paper provides updates on the epidemiology and current knowledge in PAD.
•• Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12). The paper is the latest AHA/ACC LEPAD guidelines.
•• Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. The paper is the latest ESC PAD guidelines.
Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, et al. Acute Limb Ischemia in Peripheral Artery Disease. Circulation. 2019;140(7):556–65.
Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. JAMA Cardiol. 2020.
King RW, Canonico ME, Bonaca MP, Hess CN. Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. J Soc Cardiovasc Angiogr Interv. 2022;1(6):100513.
Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, et al. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vasc Med. 2018;23(6):523–30.
Article CAS PubMed Google Scholar
•• Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation. 2018;137(4):338–50. The paper is a subgroup analysis from FOURIER demonstrating the efficacy of evolocumab in PAD patients.
Article CAS PubMed Google Scholar
• Narula N, Dannenberg AJ, Olin JW, Bhatt DL, Johnson KW, Nadkarni G, et al. Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia. J Am Coll Cardiol. 2018;72(18):2152–63. The paper highlights the pathophysiology of ALI including the role of thrombo-embolism.
Article CAS PubMed Google Scholar
Creager MA, Hamburg NM. Smoking Cessation Improves Outcomes in Patients With Peripheral Artery Disease. JAMA Cardiol. 2022;7(1):15.
Ebbert J, Burke MV, Hays JT. Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. Patient Prefer Adherence. 2016;435.
López-Laguna N, Martínez-González MA, Toledo E, Babio N, Sorlí JV, Ros E, et al. Risk of peripheral artery disease according to a healthy lifestyle score: The PREDIMED study. Atherosclerosis. 2018;275:133–40.
Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, et al. Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association. Circulation. 2019;140(13).
Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication. JAMA. 2015;314(18):1936.
Article CAS PubMed Google Scholar
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840–a1840.
Article PubMed PubMed Central Google Scholar
Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–8.
Article CAS PubMed Google Scholar
•• Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021;42(39):4013–24. The paper is the latest ESC consensus on antithrombotic therapy in PAD, including last evidence after LER.
Article CAS PubMed Google Scholar
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet. 1996;348(9038):1329–39.
Canonico ME, Piccolo R, Avvedimento M, Leone A, Esposito S, Franzone A, et al. Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. J Cardiovasc Dev Dis. 2023;10(4):164.
CAS PubMed PubMed Central Google Scholar
Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2008;30(2):192–201.
Bonaca MP, Bhatt DL, Storey RF, Steg PhG, Cohen M, Kuder J, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719–28.
Article CAS PubMed Google Scholar
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309–20.
Article CAS PubMed Google Scholar
Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, et al. Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. N Eng J Med. 2007;357(3):217–27.
Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, et al. Vorapaxar in Patients With Peripheral Artery Disease. Circulation. 2013;127(14):1522–9.
Article CAS PubMed Google Scholar
Belch JJF, Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833.e2.
Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012;22(9):1998–2006.
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. The Lancet. 2000;355(9201):346–51.
Moll F, Baumgartner I, Jaff M, Nwachuku C, Tangelder M, Ansel G, et al. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. J Endovasc Ther. 2018;25(2):158–68.
•• Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994–2004. The VOYAGER-PAD trial demonstrated the efficacy of DPI in symptomatic LEPAD patients undergoing LER.
Article CAS PubMed Google Scholar
Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation. 2020;142(23):2219–30.
Article CAS PubMed Google Scholar
Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, et al. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. J Am Coll Cardiol. 2021;78(4):317–26.
Article CAS PubMed Google Scholar
Östergren J. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17–24.
Telmisartan R. or Both in Patients at High Risk for Vascular Events. N Engl J Med. 2008;358(15):1547–59.
Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, et al. Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease. Hypertension. 2010;55(1):48–53.
Article CAS PubMed Google Scholar
•• Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. The paper is the latest ESC guidelines on dyslipidemia including LDL-C target in ASCVD patients.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7–22.
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645–654.e1.
Kumbhani DJ, Steg PhG, Cannon CP, Eagle KA, Smith SC, Goto S, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864–72.
Article CAS PubMed PubMed Central Google Scholar
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–97.
Article CAS PubMed Google Scholar
Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934–43.
Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. J Am Coll Cardiol. 2022;80(14):1366–418.
•• Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. J Am Coll Cardiol. 2019;74(9):1167–76. The paper is a subgroup analysis from ODYSSEY OUTCOMES demonstrating the efficacy of alirocumab in PAD patients.
Article CAS PubMed Google Scholar
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097–107.
Article CAS PubMed Google Scholar
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
留言 (0)